The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients
The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients
复制标题
DOI：
10.1016/j.cca.2006.02.033
复制
发表时间：
2006-09-01
影响因子：
5
通讯作者：
Wojtukiewicz, Marek
中科院分区：
文献类型：
--
作者：
Lawicki, Slawomir;Szmitkowski, Maciej;Wojtukiewicz, Marek
背景：在本研究中，我们调查了乳腺癌患者与良性乳腺肿瘤组和健康对照之间的 M-CSF 和普遍接受的肿瘤标志物（抗原 CA 15-3）的血浆水平。此外，我们将血浆 M-CSF 水平与乳腺癌的肿瘤分期进行了比较，并定义了诊断标准：敏感性、特异性、阳性和阴性预测值。此外，我们定义了 M-CSF 和 CA 15-3 的接受者操作特征 (ROC) 曲线，以及两个参数之间的相关性。 方法：测量了 80 名乳腺癌患者、17 名良性乳腺肿瘤患者和 30 名健康受试者的 M-CSF 和 CA 15-3。使用酶联免疫吸附测定（ELISA）测定M-CSF。采用微粒酶联免疫分析试剂盒（MEIA）测定CA 15-3。结果：乳腺癌患者循环M-CSF和CA 15-3水平与乳腺良性肿瘤组和对照组相比，差异有统计学意义。肿瘤分期越晚期的患者，M-CSF 和 CA 15-3 的水平也显着升高。 M-CSF 和 CA 15-3 水平之间观察到统计学上显着的正相关。 M-CSF 和 CA 15-3 诊断特异性为 95%。 M-CSF 的诊断敏感性 (59%)、阳性预测值 (97%) 和阴性预测值 (41%) 高于 CA 15-3（分别为 48.8%、95% 和 40.1%）。两种细胞因子的联合使用导致敏感性增加至70%的范围。我们观察到 M-CSF 在更晚期的乳腺肿瘤阶段具有更高的诊断敏感性。 ROC 曲线下的 M-CSF 面积 (0.801) 大于 CA 15-3 的 ROC 面积 (0.785)。结论：这些结果表明 M-CSF 是乳腺癌肿瘤标志物的良好候选者。 (c) 2006 Elsevier B.V 保留所有权利。
Background: In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls. Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values. Moreover, we defined the receiver-operating characteristics (ROC) curve for M-CSF and CA 15-3, and correlation between both parameters.Methods: M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects. M-CSF was determined using enzyme-linked immunosorbent assay (ELISA). CA 15-3 was measured using a microparticle enzyme immunoassay kit (MEIA).Results: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group. The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage. Statistically significant positive correlation was observed between the M-CSF and CA 15-3 levels. The M-CSF and CA 15-3 diagnostic specificities were 95%. The diagnostic sensitivity (59%), the positive predictive value (97%) and the negative predictive value (41%) were higher for M-CSF than for CA 15-3 (48.8%, 95% and 40.1%, respectively). The combined use of both cytokines resulted in the increase of the sensitivity to the range of 70%. We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage. The M-CSF area under the ROC curve was larger (0.801) than the ROC area of CA 15-3 (0.785).Conclusions: These results suggest that M-CSF is the good candidate for a breast cancer tumor marker. (c) 2006 Elsevier B.V All rights reserved.